Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 124Recurrence 11Neoplasms 8Immunoglobulin Light-chain Amyloidosis 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms, Plasma Cell 5Smoldering Multiple Myeloma 4Lymphoma 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Plasmacytoma 2Plasmablastic Lymphoma 2Myelodysplastic Syndromes 2Hodgkin Disease 2Hematologic Neoplasms 2Amyloidosis 2Acute Kidney Injury 2Triple Negative Breast Neoplasms 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Paraproteinemias 1Non-small Cell Lung Cancer With STK11/LKB1 Mutation 1Neoplasm, Residual 1Microsatellite Unstable Colorectal Cancer 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Plasma Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Proteostasis Deficiencies × daratumumab × 1 year × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡